Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformin in Healthy Indian Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests, 12 lead ECG and chest-x-ray. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Medical Investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.~2. Males between 18 and 50 years of age (both inclusive), who are willing to participate in the study and provide a written signed and dated informed consent.~3. Body weight more than or equal to 60 kg and BMI within the range 18.5-24.9 kg/m2 (inclusive).~4. Availability of a study volunteer for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent.~Exclusion Criteria:~1. A positive pre-study urine drug screen.~2. A positive test for HIV antibody.~3. Subject has clinically significant abnormal values of laboratory parameters.~4. Regular alcohol consumption within 6 months of the study defined as an average weekly intake of \>21 units. One unit is equivalent to 8 g of alcohol: a half-pint (\~240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits (CTRI, 2010).~5. The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).~6. Exposure to more than four new chemical entities within 12 months prior to the first dosing day.~7. Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise subject safety.~8. History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator contraindicates their participation.~9. Where participation in another study would result in donation of blood or blood products in excess of 350 ml within a 90 day period prior to this study.~10. Unwillingness or inability to follow the procedures outlined in the protocol.~11. Subject is mentally or legally incapacitated or the subject is incapable of understanding the informed consent.~12. Subject has any evidence of impaired renal, hepatic, cardiac, lung or gastrointestinal function. Study volunteers with a history of tuberculosis, epilepsy, asthma (during past 5 years), diabetes, psychosis or glaucoma will not be eligible for the study.~13. History of sensitivity to heparin or heparin-induced thrombocytopenia.~14. Regular use of tobacco- or nicotine-containing products within 6 months prior to screening.~15. Subject is intolerant to venipuncture.~16. Unable to refrain from consumption of red wine, seville oranges, grapefruit or grapefruit juice \[and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices\] from 7 days prior to the first dose of study medication.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Metformin hydrochloride prolonged release (Type: ACTIVE_COMPARATOR): 1000mg in fasting state
- metformin hydrochloride prolonged release (Type: ACTIVE_COMPARATOR): 1000mg In fed state
- Metformin hydrochloride sustained release/Glimepiride (Type: ACTIVE_COMPARATOR): 1000/2mg In fed state

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete